

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gregory et al. Art Unit TBA
Serial No. TBA
Filed March 15, 2002
Confirmation No. TBA
For IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR
Examiner TBA

March 15, 2002

PRELIMINARY AMENDMENT

TO THE ASSISTANT COMMISSIONER FOR PATENTS,
Washington, D.C. 20231

SIR:

Prior to calculating the filing fee in this matter, please
enter the following amendments in the above-referenced
application.

IN THE SPECIFICATION:

At page 1, following the Title of the Invention please
insert the following paragraph:

--This application is a divisional patent application of
U.S. Patent Application Serial Number 09/430,072 (filed October
18, 1999), which is a continuing patent application of U.S.
Patent Application Serial Number 09/189,463 (filed November 10,
1998), now abandoned, which is a continuation of prior U.S.
Patent Application Serial Number 08/600,622 (filed February 13,
1996), now abandoned.--

IN THE CLAIMS:

Please cancel claims 1-8 and 21.

Please replace Claim 17 with the following:

17. (once amended) The combination of Claim 16 wherein the cyclooxygenase-2 inhibitor is selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

3-(3,4-difluorophenyl)-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)-furanone;

4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;

4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4-[5-hydroxyethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

[2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;

4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; and

4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl]-4-oxazolyl]benzenesulfonamide.

IN THE ABSTRACT:

Please add the following Abstract:

ABSTRACT

This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds

and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

REMARKS

The purpose of the instant amendment is to add the related application information, cancel claims 1-8 and 21, and provide an abstract, thereby conforming this application to the parent application, Serial No. 09/430,072. No new matter has been added by this amendment. Favorable consideration and early allowance of all pending claims is requested.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

At page 1, following the Title of the Invention, a paragraph has been inserted.

IN THE CLAIMS:

Claims 1-8 and 21 have been cancelled.

Claim 17 has been replaced with the following:

17. (once amended) The combination of Claim 16 wherein the cyclooxygenase-2 inhibitor is selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

3- (3,4-difluorophenyl) -4- (4-methylsulfonylphenyl) -2- (5H) -furanone;

3-phenyl-4- (4-methylsulfonylphenyl) -2- (5H) -furanone;

4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl]benzenesulfonamide;

4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl]benzenesulfonamide;

4- [5- (3-fluoro-4-methoxyphenyl) -3- (difluoromethyl) -1H-pyrazol-1-yl]benzenesulfonamide;

3- [1- [4- (methylsulfonyl)phenyl] -4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

2-methyl-5- [1- [4- (methylsulfonyl)phenyl] -4-trifluoromethyl-1H-imidazol-2-yl]pyridine;

4- [2- (5-methylpyridin-3-yl) -4- (trifluoromethyl) -1H-imidazol-1-yl]benzenesulfonamide;

4- [5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

4- [5-hydroxyethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;

[2-trifluoromethyl-5- (3,4-difluorophenyl) -4-oxazolyl]benzenesulfonamide;

4- [2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; and


4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide

IN THE ABSTRACT:

Following the claims, an abstract has been added.

If there are any additional charges in this matter, please charge Deposit Account No. 19-1345.

Respectfully submitted,



Edward J. Hejlek, Reg. No. 31,525
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

EJH/PKFMkd

Express Mail No. EL890687919US